Rocket Pharmaceuticals, which recently merged with Inotek Pharmaceuticals, reported a net loss of $19.6 million, or $219.49 per share, in 2017 compared with a net loss of $7.6 million, or $84.43 per share, in 2016, according to a press release.
Research and development costs increased from $6 million in 2016 to $14.9 million in 2017, while general and administrative costs increased to $4.9 million in 2017 compared with $1.6 million in 2016.
The company had $18.1 million in cash as of Dec. 31, 2017. As of Feb. 28, after the (Read more...)
Uncategorized